Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,937 | 6 | 91.3% |
| Travel and Lodging | $824.28 | 3 | 6.9% |
| Food and Beverage | $214.09 | 2 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $9,340 | 9 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,950 | 1 | $0 (2022) |
| AstraZeneca UK Limited | $685.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $685.00 | 1 | AstraZeneca UK Limited ($685.00) |
| 2022 | $1,950 | 1 | GlaxoSmithKline, LLC. ($1,950) |
| 2017 | $9,340 | 9 | AstraZeneca Pharmaceuticals LP ($9,340) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/25/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 02/09/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 12/07/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Oncology | ||||||
| 12/07/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,648.00 | General |
| Category: Oncology | ||||||
| 06/30/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $413.60 | General |
| Category: Oncology | ||||||
| 06/30/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $321.06 | General |
| Category: Oncology | ||||||
| 06/30/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $116.09 | General |
| Category: Oncology | ||||||
| 06/03/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $98.00 | General |
| Category: Oncology | ||||||
| 06/03/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $89.62 | General |
| Category: Oncology | ||||||
| 05/22/2017 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 05/01/2017 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,416.50 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 121 | 137 | $45,767 | $10,306 |
| 2022 | 3 | 185 | 219 | $75,499 | $16,963 |
| 2021 | 5 | 225 | 279 | $101,407 | $24,007 |
| 2020 | 3 | 166 | 196 | $31,631 | $12,973 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 86 | 98 | $31,948 | $7,422 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 20 | $9,620 | $2,157 | 22.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 19 | 19 | $4,199 | $727.09 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 144 | 164 | $53,464 | $12,119 | 22.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 38 | $18,278 | $3,983 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 17 | $3,757 | $860.21 | 22.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 146 | 171 | $55,680 | $12,832 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 36 | 60 | $28,634 | $7,136 | 24.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $8,436 | $2,127 | 25.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 16 | 21 | $5,784 | $1,325 | 22.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 13 | $2,873 | $586.27 | 20.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 94 | 107 | $16,900 | $6,376 | 37.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 59 | 61 | $8,987 | $3,865 | 43.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 13 | 28 | $5,744 | $2,732 | 47.6% |
About Dr. Nadine Muskatel Tung, M.D
Dr. Nadine Muskatel Tung, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609800366.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nadine Muskatel Tung, M.D has received a total of $11,975 in payments from pharmaceutical and medical device companies, with $685.00 received in 2024. These payments were reported across 11 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($10,937).
As a Medicare-enrolled provider, Tung has provided services to 697 Medicare beneficiaries, totaling 831 services with total Medicare billing of $64,248. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 07/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1609800366
Products in Payments
- LYNPARZA (Drug) $6,386
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795